{"organizations": [], "uuid": "886ed3af5ac87cc9ec32213e9c1861f79d668292", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.marketwatch.com", "main_image": "http://s.wsj.net/public/resources/MWimages/MW-DR328_mw_soc_NS_20150801233302.png", "site_section": "http://www.marketwatch.com/subjects/politics-and-government?prop=issue&propval=commodities", "section_title": "Politics and Government - MarketWatch.com Topics", "url": "http://www.marketwatch.com/story/astrazeneca-fda-wants-more-data-on-diabetes-drug-2015-10-16", "country": "US", "title": "AstraZeneca: FDA wants more data on diabetes drug", "performance_score": 0, "site": "marketwatch.com", "participants_count": 1, "title_full": "AstraZeneca: FDA wants more data on diabetes drug - MarketWatch", "spam_score": 0.0, "site_type": "news", "published": "2015-10-16T03:00:00.000+03:00", "replies_count": 0, "uuid": "886ed3af5ac87cc9ec32213e9c1861f79d668292"}, "author": "Tapan Panchal", "url": "http://www.marketwatch.com/story/astrazeneca-fda-wants-more-data-on-diabetes-drug-2015-10-16", "ord_in_thread": 0, "title": "AstraZeneca: FDA wants more data on diabetes drug", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "LONDON--AstraZeneca PLC (AZN.LN) said Friday that the U.S. Food and Drug Administration has asked for more clinical data in relation to a new diabetes treatment.\nThe U.S. regulator has issued a letter to the company stating that it requires more data from the U.K. pharmaceutical company to support its new drug application for the fixed-dose combination of saxagliptin and dapagliflozin, which are used for treating type two diabetes in adults.\nAstraZeneca said it will work closely with the regulator to determine the next steps for the application and said it remains committed to the development of the drug.\nWrite to Tapan Panchal at tapan.panchal@wsj.com\nSubscribe to WSJ: http://online.wsj.com?mod=djnwires\n ", "external_links": [], "published": "2015-10-16T03:00:00.000+03:00", "crawled": "2015-10-16T09:43:54.576+03:00", "highlightTitle": ""}